In the intestine ( Figure 6 ), the treatment in the IUGR-VEGF and IUGR-IGF groups showed a trend to increase both the number of crypts/mm 2 ( p = 0.183) and the number of villi/mm 2 when compared with the IUGR-CON group ( p = 0.089); however, both the IUGR-VEGF and IUGR-IGF groups showed a significantly shorter villous length and a trend toward a lower crypt depth than in the IUGR-CON group ( p = 0.045 and p = 0.147, respectively). 4.
Although the changes were not statistically significant, TgHD iPSCs showed a trend toward upregulation of hexokinase 2 ( HK2 ) ( P =0.1833) and glyceraldehyde 3-phosphate dehydrogenase ( GAPDH ) ( P =0.0555), and downregulation of pyruvate kinase ( PKM ) ( P =0.2180), relative to WT iPSCs, indicating early metabolic dysregulation in TgHD iPSCs.
Additionally, other cytokines showed a trend towards statistical significance, including another Th2 response cytokine, IL-4 ( p = 0.1837) ( Figure 2 D), TNF-α ( p = 0.0690) ( Figure 2 A), and IL-6 ( p = 0.0599) ( Figure 2 B).
Finally, dogs with CMCs expressing high levels of CD109 showed a trend toward decreased survival ( p = 0.1844) compared to dogs with CMCs expressing low levels of CD109 (Fig. 4F ).
With regard to body weight, patients with obesity—meaning a BMI of more than 30—showed a trend towards less compliance than patients with normal weight or overweight (20.23 ± 5.77 vs. 21.62 ± 4 h, p = 0.185).
The VFI showed a trend towards improvement, albeit without statistical significance in either group (enhanced: p = 0.186, standard: p = 0.813), while the magnitude of change also lacked significance ( p = 0.519).
For patients with mild COVID-19, all were alive and discharged (Figure 2 A-B), but CP showed a trend toward a longer disease duration than PWC (median, 33.0 vs. 25.0 days, p = 0.187, Figure 2 C), suggesting CP with mild COVID-19 tend to have a longer recovery period.
Accordingly, treated subjects were taking higher prednisone-equivalent doses at time of COVID-19 diagnosis [5 (0–10) mg/day] than untreated subjects [0 (0–2.5) mg/day; p = 0.002] and showed a trend towards a higher frequency of concomitant immunosuppressant treatment (67% vs. 48%; p = 0.187].
While poorly differentiated tumors showed a trend toward poorer survival (HR 2.00, 95% CI 0.73–5.03, p = 0.187), this association did not reach statistical significance.
The last two ASOs, even though not significant, showed a trend for upregulation (ASO 08, p = .187; ASO 74, p = .092) (Fig. 3C and D, and Supplementary Table S2 ).
HOMA-IR showed a trend for increased insulin resistance in both the HV ( P = 0.188) and HQ ( P = 0.06) HFD groups, with no effect of Q treatment ( Figure 2(g) ) but has not reached statistical significance due to variability.
Paradoxically, patients who developed nephrotoxicity showed a trend toward better survival outcomes: median PFS was 30 months versus 20 months ( p = 0.188), and the 3-year OS rate was 77.9% versus 63.8% ( p = 0.801), though these differences were not statistically significant.
Rs13278062 showed a trend towards an association with the same direction of effect (OR = 1.19, P = 0.189, Table 1 ).
While data showed a trend towards higher NRM after MAC [21.4% (95% CI: 12.4-32.1%) vs. 13.1% (95% CI: 6.0-22.9%, P = 0.19], the cumulative incidence of relapse did not show a significant difference [29.3% (95% CI: 18.7–40.7%) vs. 39.2% (95% CI: 26.7-51.4%, P = 0.29] (Table 3 ).
2A-B ), the level of APP showed a trend toward increase ( Figure 2a-b , P = 0.19), and the protein level of Aβ42 was significantly higher in 12-month-old WT mice ( Figure 2a-b , P < 0.05).
Longer prehospital delay showed a trend toward higher mortality (adjusted OR 1.39, 95% CI 0.81–1.74; p = 0.19).
Primary outcome: PFFs incidence The pooled analysis of the three studies showed a trend towards a lower periprosthetic fracture rate in the cemented group compared to the uncemented group (RR = 0.46; 95%CI: 0.14-1.49; P = 0.19) ( Figure 2 ).
Compared to a physical relation, the difference between property and bumping ( M = 4.43, SD = 2.69) showed a trend in the predicted direction that was not statistically significant, t (98) = 1.30, p = .19, d = 0.26.
Evidence on compliance rate and the risk-reducing effect of aspirin showed a trend to lower incidence of preterm pre-eclampsia with an aspirin adherence ≥90% in comparison to <90% (OR=0.24 vs OR=0.65, p=0.19) 28 .
There were no differences in baseline Glx level between patients who went on to respond to treatment and those who did not, though responders showed a trend to have lower values (14.8 ± 1.2 vs 14.1 ± 0.93 μmol/g, t = 1.38, p = 0.19).
Patients having a SCF/TGF-α ≤4.4 showed a trend for worse survival compared to those with >4.4 (p=0.190) ( figure 1f ).
Patients with irAEs showed a trend toward improved OS (median OS 16.4 vs. 6.8 months, p = 0.19) compared to hospitalized patients without documented irAEs.
Linsitinib significantly reduced T-cell infiltration in the orbital fat of the late TSHR-immunized mice ( Figure 5B ), while the early group showed a trend to reduced T-cell infiltration after treatment with linsitinib (p= 0.19).
Lower Mcl-1 expression showed a trend towards improved OS ( Figure 3 H; p = 0.19) and correlated significantly with disease-free survival (DFS) ( Figure 3 K; p = 0.03).
4 ) measured at the first MRI timepoint did not show any difference between the control and GDM groups but showed a trend towards larger mean placental volumes in the GDM group (control: 137.1 cm 3 vs GDM: 152.1 cm 3 , P = 0.19).